One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1016/j.jacc.2013.08.1028
Copy DOI
Export
Save
Share
Cite Publication Date: Oct 1, 2013 | |
 Citations: 2 |  License type: publisher-specific-oa |
Affiliation: NorthShore University HealthSystem, Mount Sinai Hospital, Cardiovascular Research Foundation, Columbia University, Charité - Universitätsmedizin Berlin, NewYork–Presbyterian Brooklyn Methodist Hospital, Tel Aviv University, Krakow Cardiovascular Research Institute, Rambam Health Care Campus
The HORIZONS-AMI trial demonstrated that bivalirudin alone (BIV), compared to heparin plus a glycoprotein IIb/IIIa inhibitor (GPI), resulted in significantly reduced rates of major bleeding and increased event-free survival in patients with acute STEMI undergoing primary PCI. However, the additional
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
